To most of us, a vial of blood looks like a simple container of biological truth, a snapshot of what was happening inside a person at the moment the needle entered their arm. Scientists can measure its proteins, read genetic material, hunt for signs of disease, and feed the resulting data into increasingly powerful analytical systems. Yet that vial has a history. How long did it sit before processing? At what temperature? What kind of tube held it? Was it spun, transported, frozen, thawed, or stored? Each step may quietly change what researchers later believe they are seeing.

For more than four decades, HIV has challenged some of the brightest scientific minds in the world. Tremendous progress has transformed HIV from what was once almost always a fatal infection into a condition that can often be managed with modern medicines. Preventive treatments have also become increasingly effective. Yet millions of people continue to become infected every year, particularly in regions where access to healthcare remains limited. A safe, effective preventive HIV vaccine remains one of the greatest goals in global medicine because it has the potential to provide large-scale, long-lasting prevention for large numbers of high-risk populations.

A medical breakthrough is only truly a breakthrough if it can reach the person who needs it. That simple idea sits at the heart of a rapidly growing challenge in cell therapy, gene therapy and regenerative medicine. These treatments are beginning to change what doctors can offer people with serious cancers, rare genetic conditions and other diseases once considered extraordinarily difficult to treat. Some therapies can reprogram a patient’s own cells to attack cancer. Others aim to repair or replace faulty biological instructions. Their promise can sound futuristic, yet the central problem is increasingly practical: how do we turn remarkable science into care that is affordable, timely and available to everyone who could benefit?

Most of us rarely wonder what a bicycle headlamp, ceiling light or LED lens is made from. We notice whether it shines brightly, survives heat and weather, and keeps working for years. Yet hidden inside many lighting products are transparent plastics whose environmental credentials are less attractive than their optical performance. Common materials such as polycarbonate and polymethyl methacrylate are generally fossil based and resist degradation. Replacing them involves more than just choosing a greener plastic. A material that guides light must remain clear, strong, dimensionally stable and reliable while being exposed to the destructive forces of heat and light.

The work of Dr. Gary Blau and Dr. Kyle Stephens of Temple University, Philadelphia, Pennsylvania, USA asks an important question that is becoming increasingly relevant around the world. If the workplace has fundamentally changed, shouldn’t the way we measure employee deviant work behaviour change too? Their research argues the answer is yes because the consequences reach far beyond academic debate. Traditional work behaviour deviance examples include: someone deliberately arrives late, spending long coffee breaks chatting with colleagues, or working more slowly than usual. Others are spreading rumours, bullying coworkers, or damaging company property. These are the kinds of in-person, on-site deviant behaviours researchers have investigated, that is, why employees sometimes act against the interests of employing organisations.

Age-related macular degeneration, often abbreviated as AMD, is one of the leading causes of vision loss among older adults worldwide. In Asia, where populations are ageing rapidly, its impact is particularly profound. For many, the disease quietly erodes central vision, making everyday activities such as reading, driving, and recognising faces increasingly difficult. Against this backdrop, the Translational Asian Age-related Macular Degeneration Programme, or TAAP for short, has emerged as a bold and ambitious effort to confront the disease head-on. Now in its second phase, TAAP-2 represents a significant evolution in both scientific scope and clinical ambition.

In the world of nuclear energy, safety is not a single switch that can be turned on or off. It is a layered, evolving philosophy shaped by decades of engineering, research, and experience. At the heart of this philosophy lie two deceptively simple ideas: prevention and mitigation. These terms sound straightforward, yet their meaning becomes far more intricate when applied to modern reactor systems. The paper authored by Karl Fleming of KNF Consulting Services, and colleagues, invites us to rethink what these concepts truly mean, especially as nuclear technology advances into new territory.

Light is something we encounter every day, so familiar that it rarely inspires a second thought. Yet beneath its apparent simplicity lies a remarkable complexity. Light can carry information in its brightness and color, but also in its polarization and phase, subtle properties that describe how its waves oscillate and interact. For decades, these hidden dimensions of light have remained largely untapped in medicine. Now, a growing body of research is beginning to reveal their extraordinary potential.

At first glance, hydroponic farming seems like the future made real. Rows of leafy greens grow indoors, roots suspended in carefully balanced nutrient solutions, untouched by soil and shielded from many of the uncertainties of outdoor agriculture. This method promises efficiency, precision, and sustainability. It uses far less water than traditional farming and produces food in tightly controlled environments. Yet beneath this clean and modern image lies a quieter story about risk, one that flows through the very water that sustains these crops.

It would be difficult to understand the movement of water in a murky lake, or the swirling air inside a sealed chamber, without being able to see inside. For decades, scientists have relied on clever tricks to peer into such opaque environments, often adding particles or using optical techniques. But what if the fluid is too dark, too enclosed, or too delicate for those methods? A new approach, developed by researchers Lennart Kira and Dr. Jerome Noir of ETH Zurich, offers a compelling answer. It listens instead of looks.